Manufacturer
DUOPHARMA MANUFACTURING (BANGI) SDN BHD
Contents
Ciprofloxacin HCl
Indication
Treatment and postexposure prophylaxis of inhalation anthrax, Lower respiratory tract infections, Skin and soft tissue infections, Upper respiratory tract infections, Malignant otitis externa, Typhoid fever, Prostatitis, Pyelonephritis, Uncomplicated cystitis, Cystic fibrosis, Complicated cystitis, Bone and joint infections, Epididymo-orchitis, Pelvic inflammatory disease, Diarrhoea, Intra-abdominal infections, Gonococcal cervicitis, Gonococcal urethritis, Prophylaxis of meningococcal meningitis,
Instruction
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Drug interaction
Increased risk of prolonged QT interval with Class IA (e.g. quinidine, procainamide) and Class III (e.g. amiodarone, sotalol) antiarrhythmics, TCA, macrolides (e.g. erythromycin), cisapride, antipsychotics. Increased serum concentration with probenecid. May increase serum concentration and toxicity of methotrexate; CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline); xanthine derivatives (e.g. caffeine, pentoxifylline). Increased risk of tendon disorders with corticosteroids. Increased serum creatinine with cyclosporin. Increased risk of convulsions with NSAIDs. May alter serum concentrations of phenytoin. Reduced oral absorption with products containing multivalent cations (e.g. Al, Ca, Mg, Fe). May increase anticoagulant effect of vit K, warfarin.Potentially Fatal: May increase serum concentration and potentiate hypotensive and sedative effects of tizanidine. Rarely, serious and fatal seizures, status epilepticus, cardiac arrest, respiratory failure with theophylline.
Malaysia
